MDLN

Medline Inc.

Medline Inc. (MDLN) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (C-). The rating has held at C+ for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C
Factor Score 2.2 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 90.9
EV / EBITDA 19.2
Rev Growth YoY 10.4%
Gross Margin 24.4%
Price Return 3M 11.9%
Price Return 12M -2.5%
Catalyst Signal 0.00
Market Cap $52.6B
TTM Revenue $30.7B
Price / Sales 1.7
ROE 4.8%

Historical Factor Score Progression

Held C+ for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C (2.2) C- (2.0) B- (2.9) B- (3.0) C+ (2.6) C+ (2.5)
2026-11-06 C- (2.1) C- (2.1) B- (2.9) B- (2.9) C+ (2.7) C+ (2.5)
2026-10-30 C (2.2) C+ (2.8) B- (2.9) C- (2.1) C+ (2.7) C+ (2.5)
2026-10-23 C (2.2) C+ (2.8) B- (2.9) C- (2.1) C+ (2.6) C+ (2.5)
2026-10-16 C (2.2) C+ (2.8) B- (2.9) C- (2.1) C+ (2.6) C+ (2.5)
Page 1 of 4